Science & Origin

From Deep Data to
Precision Ingredients.

Enbiosis didn’t start as a supplier; we started as a microbiome analysis powerhouse. After years of processing massive biological data and winning international awards, we evolved our expertise into a global design engine.

Our Story

The Evolution of Enbiosis

Enbiosis began as a cutting-edge microbiome analysis company, building one of the world’s most advanced gut data platforms. Over 15+ years of processing real-world biological data, we accumulated a unique scientific asset: deep knowledge of how the microbiome drives specific health outcomes.

Rather than remain a diagnostics company, we made a pivotal decision — to transform that intelligence into precision nutraceutical formulations that could be licensed globally.

The result is Enbiosis 2.0: a B2B formulation platform powered by AI and validated through clinical science.

Phase 1 — Microbiome Analysis

Building gut data infrastructure. Processing thousands of patient samples. Publishing peer-reviewed clinical research across top scientific journals.

Phase 2 — Digital Twin Development

Building the AI model of the human gut microbiome. Simulating ingredient interactions across thousands of biological conditions.

Phase 3 — Formulation Engine

Translating microbiome intelligence into targeted nutraceutical blends. First clinical trial: Dry Eye Disease — completed successfully.

Phase 4 — Global Licensing Platform

Enbiosis 2.0 launches as a B2B licensing engine. 100+ formulations in development. Partnerships across US, Europe, GCC, Asia-Pacific, LATAM.

The Technology

We Simulate the Human Gut Microbiome.

Through digital twin technology, we identify condition-specific metabolic targets and design research-backed, food-grade formulations to support outcomes across gastrointestinal, ocular, cognitive, mental health, and beyond.

Trial & Error

Generic ingredients, limited data, unpredictable outcomes for consumers.

Broad-spectrum, one-size-fits-all
Limited or absent clinical backing
No biological simulation
Slow iteration cycles

Digital Twin AI

We simulate the full biological environment before a formulation ever reaches production.

We simulate the full biological environment before a formulation ever reaches production.
Peer-reviewed scientific validation
AI-modelled ingredient interaction
Optimised from thousands of simulations

The Pipeline — How We Build Formulations

Prediction

Microbiome data → Digital twin simulation → Metabolic flux prediction

Discovery

Target metabolites → Retrosynthesis search → Precursor discovery

Design

Food-grade substrates → Minimal precursor set → Personalised combinations

Validation

Iterative optimisation → Simulation-validated refinement → Clinical validation

Validation

Clinical Study Areas & Timeline

Our science is validated through carefully designed clinical studies focused on meaningful biological and health outcomes.

Prediction

Microbiome data → Digital twin simulation → Metabolic flux prediction

Urology

Chronic Prostatitis, Pelvic Pain Syndrome

Gastrointestinal

IBD, IBS, Digestive Disorders

Metabolic / Endocrine

Diabetes Mellitus, Metabolic Syndrome

Dermatology

Eczema, Psoriasis, Skin Microbiome

Neurological / Cognitive

Alzheimer’s Disease, Parkinson’s Disease

Publications

Ready to License Clinically Proven Formulations?

Explore our platform of 100+ AI-designed nutraceuticals across 5 health verticals.

From Deep Data to Precision Ingredients.

The Evolution of Enbiosis

Phase 1 — Microbiome Analysis

Phase 2 — Digital Twin Development

Phase 3 — Formulation Engine

Phase 4 — Global Licensing Platform

We Simulate the Human Gut Microbiome.

Trial & Error

Digital Twin AI

The Pipeline — How We Build Formulations

Prediction

Discovery

Design

Validation

Clinical Study Areas & Timeline

Prediction

Urology

Gastrointestinal

Metabolic / Endocrine

Dermatology

Neurological / Cognitive

Publications

Ready to License Clinically Proven Formulations?

Science

Platform

Partnership

From Deep Data to
Precision Ingredients.